|1.||Coleman, Nicholas: 3 articles (03/2014 - 11/2011)|
|2.||Miyajima, Atsushi: 2 articles (05/2014 - 07/2013)|
|3.||Komori, Tadasuke: 2 articles (05/2014 - 07/2013)|
|4.||Senba, Emiko: 2 articles (05/2014 - 07/2013)|
|5.||Morikawa, Yoshihiro: 2 articles (05/2014 - 07/2013)|
|6.||Tanaka, Minoru: 2 articles (05/2014 - 07/2013)|
|7.||Caffarel, Maria M: 2 articles (03/2014 - 10/2013)|
|8.||Vogt, T: 2 articles (12/2013 - 10/2009)|
|9.||Landthaler, M: 2 articles (12/2013 - 10/2009)|
|10.||Babilas, P: 2 articles (12/2013 - 10/2009)|
07/26/2013 - "Lack of oncostatin M receptor β leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype."
01/01/2005 - "In the present study, we showed that OSM mRNA was highly expressed in the inflamed skin during acute inflammation induced by complete Freund's adjuvant (CFA), while the expression of oncostatin M receptor (OSMR) did not change in the ipsilateral DRG. "
01/01/2005 - "Up-regulated phosphorylation of signal transducer and activator of transcription 3 and cyclic AMP-responsive element binding protein by peripheral inflammation in primary afferent neurons possibly through oncostatin M receptor."
01/27/2009 - "The TNFRs play a critical role in activating intragraft expression of transcription factors controlling innate and adaptive immunity and stress responses (interferon regulatory factor [IRF]1, IRF 8, Isgf3g, and ATF3) of cytokines and receptors mediating inflammation (TNF, interleukin [IL]-6, interferon-gamma, oncostatin M receptor [OMCR], toll-like receptor [TLR]2, and IL-2Rgamma), of chemokines and adhesion molecules that recruit inflammatory cells (Cxcl9, Cxcl11, E-selectin, and intracellular adhesion molecule [ICAM]-1), of genes involved in costimulation of T cells and processing and presentation of antigens (H2-DMb, Psmb8, and CD40), and genes that mediate the response to interferons. "
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/01/2014 - "An exciting new molecular target for the treatment of cervical squamous cell carcinoma (SCC), and possibly for SCCs at other anatomical sites, is the oncostatin M receptor (OSMR). "
03/01/2014 - "Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma."
10/01/2013 - "Oncostatin M receptor (OSMR) is commonly over-expressed in advanced cervical squamous cell carcinoma (SCC), producing a significantly worse clinical outcome. "
10/01/2013 - "Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma."
11/01/2011 - "Oncostatin M receptor (OSMR) shows frequent copy number gain and overexpression in advanced cervical squamous cell carcinoma (SCC). "
12/01/2013 - "Familial primary localized cutaneous amyloidosis with an oncostatin M receptor-β mutation, Pro694Leu."
01/01/2012 - "A new c.1845A→T of oncostatin M receptor-β mutation and slightly enhanced oncostatin M receptor-β expression in a Chinese family with primary localized cutaneous amyloidosis."
10/01/2009 - "Identification of an oncostatin M receptor mutation associated with familial primary cutaneous amyloidosis."
04/01/2010 - "FM and macular amyloidosis (MA) have been hypothesized to be identical clinical conditions, and cutaneous lichen amyloidosis (CLA) is linked to mutations in the OSMR (oncostatin M receptor) or RET (receptor tyrosine kinase) genes. "
03/01/2009 - "Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs."
03/01/2004 - "The oncostatin M receptor/gp130 ligand murine oncostatin M induces apoptosis in adrenocortical Y-1 tumor cells."
02/01/2014 - "Expression of AIF inversely correlated with that of positive NSCLC markers, e.g., dihydrodiol dehydrogenase (DDH), c-MET, short oncostatin M receptor (OSMRs), matrix metalloproteinase (MMP)-1, and HER2/neu, which were closely associated with drug resistance, tumor recurrence, metastasis and poor prognosis. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
09/20/2011 - "To explore the feasibility of detecting vimentin, oncostatin M receptor (OMSR) and tissue factor pathway inhibitor 2 (TFPI2) gene methylation status in stool samples as a noninvasive screening tool for colorectal cancer and precancerous lesions. "
09/20/2011 - "[Human stool vimentin, oncostatin M receptor and tissue factor pathway inhibitor 2 gene methylation analysis for the detection of colorectal neoplasms]."
|1.||Messenger RNA (mRNA)
|5.||Toll-Like Receptors (Toll-Like Receptor)
|6.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|7.||CD40 Ligand (CD40L)
|8.||Interleukin-6 Receptors (Interleukin 6 Receptor)